Boston Scientific Corporation (BSX) announced the acquisition of Valencia Technologies to expand its Urology portfolio into implantable tibial nerve stimulation (ITNS) for overactive bladder treatment. The FDA-approved eCoin System targets nearly 30 million U.S. adults over 40 with bothersome symptoms, but only 19% receive treatment beyond lifestyle adjustments. The eCoin implant offers minimally invasive treatment, with 68% of patients in the pivotal trial experiencing a 50% reduction in urge urinary incontinence episodes. Goldman Sachs lowered its price target on BSX but maintains a ‘Buy’ rating, focusing on the company’s organic growth potential. BSX specializes in interventional medical devices in the MedSurg and Cardiovascular segments.

Read more at Yahoo Finance: Boston Scientific (BSX) Expands Urology Portfolio with Valencia Deal, Analysts Emphasize Organic Growth